Invivo Therapeutics Holdings (NVIV) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access NVIV Annual Balance Sheets →
Reviewing balance sheet data across recent quarters allows users to assess how Invivo Therapeutics Holdings manages assets, liabilities, and equity through different cycles.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent8.58
Cash & Short-term Investments8.00
Other Current Assets0.32
Prepaid Expense, Current AS0.62
Total Current Assets9.53
Equipment/Property/Plant Net0.01
Long-term investments0.05
Prepaid Expense Other, Noncurrent PR0.00
Other Assets, Noncurrent0.05
Assets Held For Sale Not Part Of Disposal Group Current0.00
Operating Lease Right Of Use Asset-
Total Assets9.58
Liabilities
Accounts Payable, Current AC0.12
Accrued Liabilities, Current AC0.54
Total Current Liabilities0.67
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Operating Lease Liability Current-
Total Liabilities0.67
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock264.50
Retained Earnings / Accumulated Deficit-255.59
Other Equity0.00
Common Stockholder's Equity8.92
Total Stockholder's Equity8.92
Liabilities & Stockholder's Equity9.58
4 historic quarters locked

Sign in to unlock the full Invivo Therapeutics Holdings balance sheet history.

About Invivo Therapeutics Holdings Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001558370-23-018294

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.